Anebulo Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. (ANEB) is a U.S.-based clinical-stage biopharmaceutical company that has been listed on NASDAQ in the United States. The company’s strategy is highly focused: it is developing novel solutions for acute cannabis-induced toxic effects, a niche therapeutic area with potential relevance in emergency medicine and pediatrics. Anebulo was founded on April 23, 2020, as a Delaware corporation and has since operated primarily as an R&D-driven biotech rather than a commercial-stage pharmaceutical company. Its headquarters are in Austin, Texas, which gives it access to a growing U.S. life sciences ecosystem and to talent with experience across clinical development, regulatory affairs and capital markets. Anebulo’s lead program is selonabant. According to recent company disclosures, the oral formulation has completed a Phase 2 clinical trial assessing its ability to block and reverse the negative effects of acute THC intoxication in healthy adults. More recently, management has prioritized the advancement of an intravenous formulation of selonabant, which the company believes could provide a faster development path toward approval, particularly for pediatric patients exposed to cannabis toxicity. That strategic pivot underscores Anebulo’s thesis: rather than building a broad portfolio, it is attempting to establish a first-in-class or best-in-class position around a targeted medical need that remains largely underserved. From a competitive standpoint, Anebulo is a specialty microcap biotech with a concentrated pipeline and limited diversification. That can be advantageous if the lead asset succeeds, because the company would be addressing a clearly defined unmet medical need with a differentiated mechanism and a focused regulatory path. At the same time, the model carries the usual clinical-stage risks: dependency on one principal asset, uncertainty around clinical outcomes, regulatory hurdles, capital constraints and execution risk. For investors, the equity case is therefore driven more by binary development milestones than by near-term commercial revenue. Recent corporate news has been significant. In February 2026, Anebulo announced its intention to voluntarily delist from NASDAQ and deregister with the SEC, stating that the costs and burdens of remaining a public reporting company outweighed the benefits as it continued efforts to maximize value from its lead product candidate. The company also indicated that it had initiated a Phase 1 SAD study of IV selonabant in 2025, reinforcing that the lead program remains active despite the corporate restructuring. For international investors, Anebulo represents a highly specialized U.S. biotech story: focused pipeline exposure, clinical-stage optionality and elevated risk, with the additional complexity of a transition away from the public markets.